TITUSVILLE, N.J., Dec. 28, 2017 /PRNewswire/ — Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that data from a Phase 2 clinical study of intranasal esketamine, published yesterday in JAMA Psychiatry, showed a signif…
